BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, Welsh JW, Ye R, Miao H, Chang JY. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys 2020;106:90-9. [PMID: 31586665 DOI: 10.1016/j.ijrobp.2019.09.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiao Z, Li H, Xiao Y, Aggarwal C, Galperin-Aizenberg M, Pryma D, Simone CB 2nd, Feigenberg SJ, Kao GD, Fan Y. Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2021;109:1647-56. [PMID: 33333202 DOI: 10.1016/j.ijrobp.2020.12.014] [Reference Citation Analysis]
2 Tahir I, Marquardt JP, Mercaldo ND, Bourgouin PP, Wrobel MM, Mrah S, Sharp GC, Khandekar MJ, Willers H, Keane FK, Fintelmann FJ. Utility of Noncancerous Chest CT Features for Predicting Overall Survival and Noncancer Death in Patients With Stage I Lung Cancer Treated With Stereotactic Body Radiotherapy. AJR Am J Roentgenol 2022. [PMID: 35416054 DOI: 10.2214/AJR.22.27484] [Reference Citation Analysis]
3 Yang H, Wang L, Shao G, Dong B, Wang F, Wei Y, Li P, Chen H, Chen W, Zheng Y, He Y, Zhao Y, Du X, Sun X, Wang Z, Wang Y, Zhou X, Lai X, Feng W, Shen L, Qiu G, Ji Y, Chen J, Jiang Y, Liu J, Zeng J, Wang C, Zhao Q, Yang X, Hu X, Ma H, Chen Q, Chen M, Jiang H, Xu Y. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Front Oncol 2022;12:967360. [DOI: 10.3389/fonc.2022.967360] [Reference Citation Analysis]
4 Gu W, Hu M, Wang W, Shi C, Mei J. Development and Validation of a Novel Nomogram for Predicting Tumor-Distant-Metastasis in Patients with Early T1-2 Stage Lung Adenocarcinoma. Ther Clin Risk Manag 2020;16:1213-25. [PMID: 33328735 DOI: 10.2147/TCRM.S272748] [Reference Citation Analysis]
5 Zeng X, Zhu S, Xu C, Wang Z, Su X, Zeng D, Long H, Zhu B. Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy. Med Sci Monit 2020;26:e922576. [PMID: 32893263 DOI: 10.12659/MSM.922576] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lubgan D, Semrau S, Lambrecht U, Gaipl US, Fietkau R. 12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma? Strahlenther Onkol 2021. [PMID: 34255094 DOI: 10.1007/s00066-021-01811-3] [Reference Citation Analysis]
7 Duijm M, Oomen-de Hoop E, van Voort van der Zyp N, van de Vaart P, Tekatli H, Hoogeman M, Senan S, Nuyttens J. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma. Radiother Oncol 2021;156:223-30. [PMID: 33418006 DOI: 10.1016/j.radonc.2020.12.038] [Reference Citation Analysis]
8 Keit E, Coutu B, Zhen W, Zhang C, Lin C, Bennion N, Ganti AK, Ernani V, Baine M. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. Ann Transl Med 2021;9:227. [PMID: 33708854 DOI: 10.21037/atm-20-6710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yang Y, Zhang T, Zhou Z, Liang J, Chen D, Feng Q, Xiao Z, Hui Z, Lv J, Deng L, Wang X, Wang W, Wang J, Liu W, Zhai Y, Wang J, Bi N, Wang L. Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Thorac Cancer 2021. [PMID: 34927371 DOI: 10.1111/1759-7714.14218] [Reference Citation Analysis]
10 Shahrokh S, Mansouri V, Razzaghi M. Assessment of the SRC Inhibition Role in the Efficacy of Breast Cancer Radiotherapy. J Lasers Med Sci 2019;10:S18-22. [PMID: 32021668 DOI: 10.15171/jlms.2019.S4] [Reference Citation Analysis]
11 Lee NS, Shafiq J, Field M, Fiddler C, Varadarajan S, Gandhidasan S, Hau E, Vinod SK. Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort. Radiat Oncol 2022;17:74. [PMID: 35418206 DOI: 10.1186/s13014-022-02050-1] [Reference Citation Analysis]
12 Salas M, Henderson M, Sundararajan M, Tu N, Islam Z, Ebeid M, Horne L. Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review. PLoS One 2021;16:e0252925. [PMID: 34143813 DOI: 10.1371/journal.pone.0252925] [Reference Citation Analysis]